A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.

Purpose: To describe an improved understanding of the regression patterns following off-label intravitreal bevacizumab (IVB) treatment for retinopathy of prematurity (ROP).

Design: Retrospective cohort study.

Methods: All infants treated with IVB for type 1 ROP at a single institution from June 2013 to March 2018 were retrospectively reviewed and the amount of retinal nonperfusion on fluorescein angiogram was calculated.